- Home
- GPRK vs MLYS Comparison
GPRK vs MLYS Comparison
Compare GPRK & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRK
- MLYS
- Stock Information
- Founded
- GPRK 2002
- MLYS 2019
- Country
- GPRK Colombia
- MLYS United States
- Employees
- GPRK N/A
- MLYS N/A
- Industry
- GPRK Oil & Gas Production
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- GPRK Energy
- MLYS Health Care
- Exchange
- GPRK Nasdaq
- MLYS Nasdaq
- Market Cap
- GPRK 475.6M
- MLYS 510.6M
- IPO Year
- GPRK N/A
- MLYS 2023
- Fundamental
- Price
- GPRK $8.02
- MLYS $13.64
- Analyst Decision
- GPRK Strong Buy
- MLYS Strong Buy
- Analyst Count
- GPRK 2
- MLYS 3
- Target Price
- GPRK $12.50
- MLYS $27.00
- AVG Volume (30 Days)
- GPRK 847.8K
- MLYS 1.5M
- Earning Date
- GPRK 03-05-2025
- MLYS 05-08-2025
- Dividend Yield
- GPRK 7.44%
- MLYS N/A
- EPS Growth
- GPRK N/A
- MLYS N/A
- EPS
- GPRK 1.84
- MLYS N/A
- Revenue
- GPRK $660,800,000.00
- MLYS N/A
- Revenue This Year
- GPRK N/A
- MLYS N/A
- Revenue Next Year
- GPRK $4.76
- MLYS N/A
- P/E Ratio
- GPRK $4.15
- MLYS N/A
- Revenue Growth
- GPRK N/A
- MLYS N/A
- 52 Week Low
- GPRK $7.24
- MLYS $8.24
- 52 Week High
- GPRK $11.72
- MLYS $18.29
- Technical
- Relative Strength Index (RSI)
- GPRK 41.07
- MLYS 62.64
- Support Level
- GPRK $7.54
- MLYS $9.69
- Resistance Level
- GPRK $8.34
- MLYS $18.29
- Average True Range (ATR)
- GPRK 0.45
- MLYS 1.23
- MACD
- GPRK -0.02
- MLYS 0.55
- Stochastic Oscillator
- GPRK 29.44
- MLYS 48.45
About GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil and Argentina. The company generates revenue from the sale of crude oil, condensate and natural gas net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.